Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L, Gardner J, Chen Q, Schmidt C, Down M, Elliott SL, Pye SJ, Firat H, Lemonnier FA, Cebon J, Suhrbier A. Mateo L, et al. J Immunol. 1999 Oct 1;163(7):4058-63. J Immunol. 1999. PMID: 10491010
Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine.
Mateo L, Gardner J, Suhrbier A. Mateo L, et al. AIDS Res Hum Retroviruses. 2001 Oct 10;17(15):1447-53. doi: 10.1089/088922201753197114. AIDS Res Hum Retroviruses. 2001. PMID: 11679157
Half the vaccinated animals remained PCR negative after challenge, whereas the remaining half and the placebo group became PCR positive within 4 weeks postchallenge (Hislop AD, Good MF, Mateo L, Gardner J, Gatei MH, Daniel RCW, Meyers BV, Lavin MF, and Suhrbier A: N …
Half the vaccinated animals remained PCR negative after challenge, whereas the remaining half and the placebo group became PCR positive with …
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A. Maraskovsky E, et al. Among authors: mateo l. Clin Cancer Res. 2004 Apr 15;10(8):2879-90. doi: 10.1158/1078-0432.ccr-03-0245. Clin Cancer Res. 2004. PMID: 15102697
H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel ML, Jack RW, Jung G, Kosmatopoulos K, Mateo L, Suhrbier A, Lemonnier FA, Langlade-Demoyen P. Firat H, et al. Among authors: mateo l. Eur J Immunol. 1999 Oct;29(10):3112-21. doi: 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q. Eur J Immunol. 1999. PMID: 10540322 Free article.
214 results